<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898284</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI18/OSCILLO</org_study_id>
    <secondary_id>2018-A02300-55</secondary_id>
    <nct_id>NCT03898284</nct_id>
  </id_info>
  <brief_title>Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>OSCILLO</acronym>
  <official_title>Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the
      current definition of disease progression (fast decline in lung function) in idiopathic
      pulmonary fibrosis. There is a need for techniques allowing to characterize disease
      progression earlier, so that treatment may be adapted as early as possible in the lack of a
      response.

      Hypothesis. Our hypothesis is that 3-month changes of lung function parameters measured by a
      novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in
      idiopathic pulmonary fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the
      current definition of disease progression (fast decline in lung function) in idiopathic
      pulmonary fibrosis. There is a need for techniques allowing to characterize disease
      progression earlier, so that treatment may be adapted as early as possible in the lack of a
      response.

      Hypothesis. Our hypothesis is that 3-month changes of lung function parameters measured by a
      novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in
      idiopathic pulmonary fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the 5-Hz reactance of the respiratory system (Xsr5) variation at 3 months, for the diagnosis of rapid decline in lung function.</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Receiver operating characteristics curves will be used to determine diagnostic performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance of the 3-month variation in additional impulse oscillometry parameters for the diagnosis of rapid decline in lung function</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Receiver operating characteristics curves will be used to determine diagnostic performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of baseline impulse oscillometry parameters for the diagnosis of rapid decline in lung function</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Receiver operating characteristics curves will be used to determine diagnostic performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess correlations between impulse oscillometry parameters and forced vital capacity</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Forced vital capacity is the total amount of air exhaled during the Forced expiratory volume test (how much air a person can exhale during a forced breath)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess correlations between impulse oscillometry parameters and exertional dyspnea</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Dyspnea is assessed by the baseline dyspnea questionnaire and the transitional dyspnea questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess correlations between impulse oscillometry parameters and the extent of either fibrosis or emphysema lesions on CT scans</measure>
    <time_frame>Baseline</time_frame>
    <description>Lesions are scored by trained observers.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Impulse Oscillometry</arm_group_label>
    <description>Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Impulse Oscillometry</intervention_name>
    <description>Impulse Oscillometry will be performed in addition to usual care</description>
    <arm_group_label>Impulse Oscillometry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Idiopathic Pulmonary Fibrosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 45 years.

          -  Idiopathic Pulmonary Fibrosis defined Interstitial Lung Diseases with 1) lack of any
             known cause for Interstitial Lung Diseases and 2) either the &quot;definite usual
             interstitial pneumonia&quot; pattern at CT scan, or the usual interstitial pneumonia
             (definite, probable or possible) pattern at lung biopsy, according to the Lung
             Function Group of the French Pulmonology Society criteria.

        Exclusion Criteria:

          -  History of chronic obstructive airway disease.

          -  History of congestive heart failure.

          -  Emphysema-fibrosis syndrome, defined as emphysematous lesions involving &gt;15% of the
             lung area at the level of the aortic arch (upper lobes).

          -  History of lower respiratory infection or acute respiratory failure of any cause less
             than 90 days before inclusion.

          -  Opposition to data processing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent PLANTIER, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent PLANTIER, MD-PhD</last_name>
    <phone>02 47 47 98 44</phone>
    <phone_ext>+33</phone_ext>
    <email>laurent.plantier@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Respiratory Functional Explorations, University Hospital, Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PEREZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry PEREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Respiratory Functional Explorations, University Hospital, Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Arnaud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud Arnaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of digestive physiology, urinary, respiratory and exercise, University Hospital, Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie NETCHITAILO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie NETCHITAILO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonology Department, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PLANTIER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent PLANTIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Impulse Oscillometry</keyword>
  <keyword>Forced Vital Capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

